CCM
EVLO

CAAS Capital Management’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History

CAAS Capital Management’s Portfolio EVLO Stock Details EVLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-4,125
Closed -$883K – 1381
2021
Q1 		$883K Buy
+4,125
New +$1.14M 0.01% 825
2020
Q4 		– Sell
-1,637
Closed -$173K – 953
2020
Q3 		$173K Sell
1,637
-4,613
-74% -$420K ﹤0.01% 445
2020
Q2 		$613K Buy
+6,250
New +$547K 0.02% 296

Other funds holding EVLO

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $22.6B AUM 40.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

CAAS Capital Management's EVLO Position: Q2 2021 in Review

CAAS Capital Management sold out of Evelo Biosciences, Inc. Common Stock (EVLO) in Q2 2021, closing a stake of 4,125 shares — an estimated $883K sold.

CAAS Capital Management first reported a position in EVLO in Q2 2020 and held it in 3 quarters. The position peaked at $883K in Q1 2021. 66 funds tracked by Wall St. Rank hold EVLO as of Q2 2021.

  • CAAS Capital Management reported no remaining Evelo Biosciences, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • CAAS Capital Management sold 4,125 Evelo Biosciences, Inc. Common Stock shares in Q2 2021, an estimated $883K.
  • CAAS Capital Management first reported a position in Evelo Biosciences, Inc. Common Stock in Q2 2020 and held it in 3 quarters.
  • CAAS Capital Management's Evelo Biosciences, Inc. Common Stock position peaked at $883K in Q1 2021.
  • 66 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q2 2021.

Based on CAAS Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.